Dianthus Inks Licensing Deal with Chinese Biotech; C4 Targets $125M Offering

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously...

Dianthus inks licensing deal with Chinese biotech; C4 targets $125M offering

Plus, news about Merck, Beijing Jacobio, Immunai, BridGene Biosciences and Spyre Therapeutics: 🇨🇳 Dianthus Therapeutics licenses autoimmune asset from China: The biotech will pay $30 million upfront to Nanjing Leads Biolabs ...